January 31, 2024
(press release)
–
B•R•A•H•M•S™ sFlt-1/PlGF KRYPTOR™ Test System is available through physicians and is the first FDA-cleared biomarker test to aid in the risk assessment of progression to preeclampsia with severe features, a leading cause of maternal and fetal mortality in the
Preeclampsia is a condition unique to pregnancy that affects 2-5% of all pregnancies and is a major cause of maternal and neonatal morbidity and mortality in
The new test, developed by Thermo Fisher Scientific and named one of
The test result, a ratio of these two biomarkers, in conjunction with other laboratory tests and clinical assessments, helps clinicians identify which patients hospitalized for hypertensive disorders of pregnancy may be at risk of progressing to severe features of preeclampsia within the next two weeks of the test. This was validated by the PRAECIS study, which examined more than 1,000 pregnant women across 18 hospitals in the
The blood-based test is intended for use in singleton pregnancies between 23+0 and 34+6/7 weeks gestation. Pregnant women who test positive based on the risk stratification sFlt-1/PlGF ratio ≥ 40, along with other indicators of disease, can receive enhanced surveillance and accelerated care before severe features develop. "
For more information, visit https://womenshealth.labcorp.com/providers/pregnancy and click on the "second and third trimester tab." About
References: View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-launches-new-test-for-risk-assessment-and-prognosis-of-severe-preeclampsia-in-pregnant-women-302049196.html SOURCE
Media: Kimbrel Arculeo, 336-436-8263, Media@Labcorp.com, Investors: Christin O'Donnell, 336-436-5076, Investor@Labcorp.com
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.